<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="d8929056-e1a4-4cb0-bfc5-a9abe7fe1b80"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use METAXALONE TABLETS, 640 mg, safely and effectively. See full prescribing information for METAXALONE TABLETS, 640 mg.
 <br/>
      <br/>
METAXALONE tablets, for oral use
 <br/>
Initial U.S. Approval: 1962
</title>
   <effectiveTime value="20250512"/>
   <setId root="fc6de1a6-26aa-47ac-a5d2-bf127a6ca563"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="117466866"/>
            <name>INA Pharmaceutics Inc</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="2e0c2f95-8bd6-e4ae-e063-6294a90ab44b"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250212"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="74157-018" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Metaxalone</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Metaxalone</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8C3Z4148WZ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALGINIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H77VEI93A8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C YELLOW NO. 6</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="26CD3J2R0C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL ALGINATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="640"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="1NMA9J598Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METAXALONE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="1NMA9J598Y" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METAXALONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="74157-018-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250210"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA022503" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250210"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="pink" xsi:type="CE">
                              <originalText>light pink to pink</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">M640</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="19" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_a9837f53-9600-4e1e-b633-fca26f83c355">
               <id root="00784843-10f3-4c8a-bc09-7a18293fb50c"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Metaxalone Tablets, 640 mg, are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions in adults and pediatric patients 13 years of age and older.</paragraph>
               </text>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Metaxalone Tablets, 640 mg, is a muscle relaxant, indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions in adult and pediatric patients 13 years of age and older. (<linkHtml href="#LINK_a9837f53-9600-4e1e-b633-fca26f83c355">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_0c67360e-3624-4be8-9869-080cb40dbbad">
               <id root="a020bed3-82c2-4b6d-af57-7f35b2cf6654"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>The recommended dosage of Metaxalone Tablets, 640 mg in adults and pediatric patients 13 years of age and older is 640 mg taken orally with or without food, three to four times a day. The maximum recommended daily dosage is 2,560 mg (one tablet four times a day).</paragraph>
                  <paragraph>Metaxalone Tablets, 640 mg and SKELAXIN 800 mg are not mutually substitutable on a mg-to-mg basis due to differences in pharmacokinetic profiles <content styleCode="italics">[see <linkHtml href="#L622706be-d54b-4e88-97d9-79aa90e50fb0">Warnings and Precautions (5.3)</linkHtml> and <linkHtml href="#L51bf7da3-a625-4cfb-a56f-bf3df03963df">Clinical Pharmacology (12.3)</linkHtml>].  </content>When it is appropriate to switch a patient taking SKELAXIN 800 mg on an empty stomach to Metaxalone Tablets, 640 mg:</paragraph>
                  <list listType="unordered">
                     <item>Stop SKELAXIN 800 mg <content styleCode="italics">three</content> times a day and start Metaxalone Tablets 640 mg <content styleCode="italics">three</content> times a day on an empty stomach, OR</item>
                     <item>Stop SKELAXIN 800 mg <content styleCode="italics">four</content> times a day and start Metaxalone Tablets 640 mg <content styleCode="italics">four</content> times a day on an empty stomach.</item>
                  </list>
                  <paragraph>For patients who have been taking either product with food, do not switch between SKELAXIN 800 mg and Metaxalone Tablets, 640 mg.</paragraph>
               </text>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Recommended dosage in adults and pediatric patients 13 years of age and older is 640 mg taken orally, with or without food, three to four times a day (<linkHtml href="#LINK_0c67360e-3624-4be8-9869-080cb40dbbad">2</linkHtml>)</item>
                           <item>Maximum recommended daily dosage is 2,560 mg (one tablet four times a day) (<linkHtml href="#LINK_0c67360e-3624-4be8-9869-080cb40dbbad">2</linkHtml>)</item>
                           <item>Metaxalone Tablets 640 mg and SKELAXIN 800 mg tablets are not mutually substitutable on a mg-to-mg basis due to differences in pharmacokinetic profiles (<linkHtml href="#L622706be-d54b-4e88-97d9-79aa90e50fb0">5.3</linkHtml>, <linkHtml href="#L51bf7da3-a625-4cfb-a56f-bf3df03963df">12.3</linkHtml>). When it is appropriate to switch a patient taking SKELAXIN 800 mg on an empty stomach to Metaxalone Tablets, 640 mg (<linkHtml href="#LINK_0c67360e-3624-4be8-9869-080cb40dbbad">2</linkHtml>):<list listType="unordered">
                                 <item>Stop SKELAXIN 800 mg <content styleCode="italics">three</content> times a day and start Metaxalone Tablets 640 mg <content styleCode="italics">three</content> times a day on an empty stomach OR</item>
                                 <item>Stop SKELAXIN 800 mg <content styleCode="italics">four</content> times a day and start Metaxalone Tablets 640 mg <content styleCode="italics">four</content> times a day on an empty stomach.</item>
                              </list>
                           </item>
                           <item>For patients who have been taking either product with food, do not switch between SKELAXIN 800 mg and Metaxalone Tablets, 640 mg (<linkHtml href="#LINK_0c67360e-3624-4be8-9869-080cb40dbbad">2</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L5fadae0d-a8c0-4443-90da-cf7d6a821cf6">
               <id root="d4732fcc-dea6-4fd4-97ab-a12cb1c40134"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Tablets: 640 mg oval, peach-colored, debossed with M640 on one side and without markings on the other side.</paragraph>
               </text>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 640 mg. (<linkHtml href="#L5fadae0d-a8c0-4443-90da-cf7d6a821cf6">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Lddce86aa-b6ac-40f3-b4e8-b068c93f371e">
               <id root="aa4635f1-e095-4ec9-af2f-f7a59f69d674"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>The use of Metaxalone Tablets, 640 mg is contraindicated in patients with:</paragraph>
                  <list listType="unordered">
                     <item>Known hypersensitivity to any components of this product.</item>
                     <item>Known tendency for drug-induced, hemolytic, or other anemias.</item>
                     <item>Severe renal or hepatic impairment.</item>
                  </list>
               </text>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>• Known hypersensitivity to any components of this product. (<linkHtml href="#Lddce86aa-b6ac-40f3-b4e8-b068c93f371e">4</linkHtml>) <br/> • Known tendency to drug induced, hemolytic, or other anemias. (<linkHtml href="#Lddce86aa-b6ac-40f3-b4e8-b068c93f371e">4</linkHtml>) <br/> • Severe renal or hepatic impairment. (<linkHtml href="#Lddce86aa-b6ac-40f3-b4e8-b068c93f371e">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L54c51b3d-c0e5-49cd-834f-b8915877897f">
               <id root="6b4501cd-50fc-4b39-92b2-6415397fc6f7"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="underline">Serotonin Syndrome</content>: Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs and with the use of metaxalone as the only serotonergic drug taken at a dosage higher than the recommended dosage. If concomitant use with another serotonergic drug is warranted, carefully observe the patient, particularly during treatment initiation and dosage increases. Discontinue Metaxalone Tablets, 640 mg if serotonin syndrome is suspected or it occurs. (<linkHtml href="#Laa73a6ef-00cc-40a9-8a9e-4869ba0c3b2b">5.1</linkHtml>, <linkHtml href="#L718e5aba-deb7-44d4-a34b-1ba1729b2725">7.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Central Nervous System (CNS) Depression</content>: Metaxalone Tablets, 640 mg may impair mental and/or physical abilities required for the performance of hazardous tasks, such as operating machinery or driving a motor vehicle, and may enhance the effects of other CNS depressants including alcohol. Follow patients closely for signs and symptoms of respiratory depression and sedation. If concomitant use with another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases. (<linkHtml href="#Lc1985dd8-a620-41b2-860e-0ef58adff08d">5.2</linkHtml>, <linkHtml href="#Lb540b148-9955-41bc-80fc-ae7532630b1e">7.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Risk with Inappropriate Switching to Metaxalone Tablets, 640 mg</content> Inappropriate switching on a mg-to-mg basis from SKELAXIN (metaxalone) tablets, 800 mg to Metaxalone Tablets, 640 mg to achieve the same total daily metaxalone dosage may result in a clinically significant increase in metaxalone exposure which may increase the risk of metaxalone-associated adverse reactions including CNS depression. Metaxalone Tablets, 640 mg and SKELAXIN (metaxalone) tablets, 800 mg are not mutually substitutable on a mg-to-mg basis (<linkHtml href="#L622706be-d54b-4e88-97d9-79aa90e50fb0">5.3</linkHtml>, <linkHtml href="#L51bf7da3-a625-4cfb-a56f-bf3df03963df">12.3</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Laa73a6ef-00cc-40a9-8a9e-4869ba0c3b2b">
                     <id root="bfcf0ece-2eba-4944-b8d6-572e375919fe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Serotonin Syndrome</title>
                     <text>
                        <paragraph>Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs <content styleCode="italics">[see <linkHtml href="#L9d19d981-a61d-4e6f-9c01-b808e6b7da03">Drug Interactions (7)</linkHtml>] </content>and with the use of metaxalone as the only serotonergic drug taken at a dosage higher than the recommended dosage <content styleCode="italics">[see <linkHtml href="#L1dc5d5d6-29ac-48c6-a9fa-96907f4c82dc">Overdosage (10)</linkHtml>]</content>. Serotonergic drugs include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, opioids (particularly fentanyl, meperidine, and methadone), drugs that affect the serotonergic neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and drugs that impair metabolism of serotonin (including monoamine oxidase (MAO) inhibitors, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) <content styleCode="italics">[see <linkHtml href="#Lb540b148-9955-41bc-80fc-ae7532630b1e">Drug Interactions (7.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination, rigidity), and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). The onset of symptoms generally occurs within several hours to a few days after initiation of a serotonergic drug but may occur later than that.</paragraph>
                        <paragraph>If concomitant use of Metaxalone Tablets, 640 mg and another serotonergic drug is warranted, reassess the patient, particularly during treatment initiation and dosage modification. Discontinue Metaxalone Tablets, 640 mg if serotonin syndrome is suspected or occurs.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="Lc1985dd8-a620-41b2-860e-0ef58adff08d">
                     <id root="61aa9083-6b5b-4cf5-8f2b-d4b26a963d52"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Central Nervous System Depression</title>
                     <text>
                        <paragraph>Because of central nervous system (CNS) depressant effects, metaxalone may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle, especially when used with other CNS depressants including alcohol. Geriatric patients may be especially susceptible to CNS depression associated with metaxalone use. When used concomitantly, the sedative effects of metaxalone and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive <content styleCode="italics">[see <linkHtml href="#L9d19d981-a61d-4e6f-9c01-b808e6b7da03">Drug Interactions (7)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Follow patients treated with Metaxalone Tablets, 640 mg closely for signs and symptoms of respiratory depression and sedation. If concomitant use of metaxalone and another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases. </paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="L622706be-d54b-4e88-97d9-79aa90e50fb0">
                     <id root="204a1d21-aa79-4b3d-9fdb-fecefd44aff0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Risk with Inappropriate Switching to Metaxalone Tablets, 640 mg</title>
                     <text>
                        <paragraph>Inappropriate switching on a mg-to-mg basis from SKELAXIN (metaxalone) tablets, 800 mg to Metaxalone Tablets, 640 mg to achieve the same total daily metaxalone dosage may result in a clinically significant increase in metaxalone exposure which may increase the risk of metaxalone-associated adverse reactions including CNS depression.  For example, it is inappropriate to switch from four SKELAXIN 800 mg tablets (3,200 mg) per day to five tablets of Metaxalone Tablets, 640 mg (3,200 mg) per day [1.25 times the maximum recommended daily dosage of 2,560 mg] <content styleCode="italics">[see <linkHtml href="#LINK_0c67360e-3624-4be8-9869-080cb40dbbad">Dosage and Administration (2)</linkHtml>].  </content>Metaxalone Tablets 640 mg and SKELAXIN (metaxalone) tablets, 800 mg are not mutually substitutable on a mg-to-mg basis <content styleCode="italics">[see <linkHtml href="#L51bf7da3-a625-4cfb-a56f-bf3df03963df">Clinical Pharmacology (12.3)</linkHtml>]</content>.  </paragraph>
                        <paragraph>It is generally inappropriate to switch between Metaxalone Tablets, 640 mg and SKELAXIN 800 mg to mediate metaxalone-associated adverse reactions.</paragraph>
                        <paragraph>For recommendations on how to switch from SKELAXIN (metaxalone) tablets, 800 mg, to Metaxalone Tablets, 640 mg, see <content styleCode="italics">
                              <linkHtml href="#LINK_0c67360e-3624-4be8-9869-080cb40dbbad">Dosage and Administration (2)</linkHtml>. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L52cc221e-fcb0-40d8-85ab-488612fc9d2c">
               <id root="c546d3f1-0d28-45ca-b518-51b9a224c074"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions associated with the use of metaxalone were identified in clinical studies or postmarketing reports.  Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.  The most frequent reactions to metaxalone were:</paragraph>
                  <list listType="unordered">
                     <item>
                        <content styleCode="underline">CNS</content>: drowsiness, dizziness, headache, and nervousness or “irritability”</item>
                     <item>
                        <content styleCode="underline">Digestive</content>: nausea, vomiting, gastrointestinal upset.</item>
                  </list>
                  <paragraph>Other adverse reactions were:</paragraph>
                  <list listType="unordered">
                     <item>
                        <content styleCode="underline">Allergic</content>:  anaphylaxis have been reported with metaxalone.</item>
                     <item>
                        <content styleCode="underline">CNS</content>: cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs and with the use of metaxalone as the only serotonergic drug taken at a dosage higher than the recommended dosage <content styleCode="italics">[see <linkHtml href="#Laa73a6ef-00cc-40a9-8a9e-4869ba0c3b2b">Warnings and Precautions (5.1)</linkHtml>, <linkHtml href="#Lb540b148-9955-41bc-80fc-ae7532630b1e">Drug Interactions (7.2)</linkHtml>, and <linkHtml href="#L1dc5d5d6-29ac-48c6-a9fa-96907f4c82dc">Overdosage (10)</linkHtml>]. </content>
                     </item>
                     <item>
                        <content styleCode="underline">Hematologic</content>: leucopenia; hemolytic anemia.</item>
                     <item>
                        <content styleCode="underline">Hepatobiliary</content>: jaundice.</item>
                     <item>
                        <content styleCode="underline">Immune System</content>: hypersensitivity reaction, rash with or without pruritus.</item>
                  </list>
               </text>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions to Metaxalone Tablets, 640 mg include drowsiness, dizziness, headache, and nervousness or “irritability”, nausea, vomiting, gastrointestinal upset. (<linkHtml href="#L52cc221e-fcb0-40d8-85ab-488612fc9d2c">6</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Primus Pharmaceuticals, Inc. at 1-877-526-4040 and <content styleCode="underline">www.primusrx.com</content> or FDA at 1-800-FDA-1088 or <content styleCode="italics">
                                 <content styleCode="underline">www.fda.gov/medwatch.</content>
                              </content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L9d19d981-a61d-4e6f-9c01-b808e6b7da03">
               <id root="150ae1ab-b948-4f4a-a662-1f73cb317bb4"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text/>
               <effectiveTime value="20250512"/>
               <component>
                  <section ID="L718e5aba-deb7-44d4-a34b-1ba1729b2725">
                     <id root="edd6133f-2745-4af4-87ac-2cb02c632e9c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Serotonergic Drugs</title>
                     <text>
                        <paragraph>If concomitant use of Metaxalone Tablets, 640 mg and another serotonergic drug is warranted, carefully observe the patient, particularly during treatment initiation and dosage modification. Discontinue Metaxalone Tablets, 640 mg if serotonin syndrome is suspected or if it occurs.</paragraph>
                        <paragraph>Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs <content styleCode="italics">[see <linkHtml href="#Laa73a6ef-00cc-40a9-8a9e-4869ba0c3b2b">Warnings and Precautions (5.1)</linkHtml>]. </content>
                        </paragraph>
                        <paragraph>Serotonergic drugs include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, opioids (particularly fentanyl, meperidine, and methadone), drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="Lb540b148-9955-41bc-80fc-ae7532630b1e">
                     <id root="d7f6e60a-030d-441d-bd06-647abac03722"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Depressants</title>
                     <text>
                        <paragraph>If concomitant use of Metaxalone Tablets, 640 mg and another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage modification. </paragraph>
                        <paragraph>Due to the additive pharmacologic effect, concomitant use of Metaxalone Tablets, 640 mg with other CNS depressants may increase the risk of sedation and respiratory depression <content styleCode="italics">[see <linkHtml href="#Lc1985dd8-a620-41b2-860e-0ef58adff08d">Warnings and Precautions (5.2)</linkHtml>]. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="Lb198f9ce-ccdc-4770-99d4-8461b795b041">
                     <id root="ece5de33-a2b9-4171-b18b-609597ffd1e6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Interaction of Metaxalone with Benedict’s Tests</title>
                     <text>
                        <paragraph>False-positive Benedict's tests, due to an unknown reducing substance, have been noted in metaxalone-treated patients. A glucose-specific test will differentiate findings.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L318d73cd-94d9-428a-9540-621b6a7e78c2">
               <id root="59b49442-f70d-4374-b0ce-45bb844e4d7e"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="underline">Geriatric Use</content>:  Geriatric patients may be especially susceptible to CNS depression associated with Metaxalone Tablets, 640 mg use. (<linkHtml href="#L0e0e2c27-0c31-4457-84d1-f98ca1adb662">8.5</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hepatic Impairment</content>:  Consider additional monitoring in patients with mild to moderate hepatic impairment.  (<linkHtml href="#Lddce86aa-b6ac-40f3-b4e8-b068c93f371e">4</linkHtml>, <linkHtml href="#L5a5d84fa-8938-4d85-8317-bea1c79cb8c7">8.6</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Renal impairment</content>:  Consider additional monitoring in patients with mild to moderate renal impairment (<linkHtml href="#Lddce86aa-b6ac-40f3-b4e8-b068c93f371e">4</linkHtml>, <linkHtml href="#L93ff90ff-b6c0-43fd-88fb-8c9f840ea5d0">8.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="L1d7bd737-a91b-4950-8cc6-893fa181b5cc">
                     <id root="e0e8d867-8cb2-4af3-ae86-9752330a6e6c"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph styleCode="Default First">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no available data on metaxalone use in pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes despite decades of metaxalone use. Reproduction studies in rats have not revealed evidence of impaired fertility or harm to fetus due to metaxalone.</paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="L0018c183-9c72-48cb-9ef6-0d091948f4dd">
                     <id root="2df31498-27cb-f165-e063-6394a90a4695"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data on the presence of metaxalone or its metabolite in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for metaxalone and any potential adverse effects on the breastfed infant from metaxalone or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20230613"/>
                  </section>
               </component>
               <component>
                  <section ID="Lc563a50e-846b-4ac0-8702-394ca91e3ce6">
                     <id root="3a660286-aeeb-474f-80e3-372d0e4b2fb2"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Metaxalone Tablets, 640 mg are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions in pediatric patients 13 years of age and older.</paragraph>
                        <paragraph>The safety and effectiveness of Metaxalone Tablets, 640 mg in pediatric patients less than 13 years of age have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="L0e0e2c27-0c31-4457-84d1-f98ca1adb662">
                     <id root="05a820e8-69cb-43d2-b544-482607aa04ea"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of Metaxalone Tablets, 640 mg did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients. The effects of age on the pharmacokinetics of Metaxalone Tablets, 640 mg have not been evaluated. Geriatric patients may be especially susceptible to CNS depression associated with metaxalone use <content styleCode="italics">[see <linkHtml href="#Lc1985dd8-a620-41b2-860e-0ef58adff08d">Warnings and Precautions (5.2)</linkHtml>]. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="L5a5d84fa-8938-4d85-8317-bea1c79cb8c7">
                     <id root="c2966965-b3bd-490b-97ed-6f607d81fa45"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph>Metaxalone Tablets. 640 mg are contraindicated in patients with severe hepatic impairment<content styleCode="italics">. </content>Metaxalone Tablets, 640 mg should be used with caution and additional monitoring should be considered in patients with mild to moderate hepatic impairment. The effect of hepatic impairment on metaxalone pharmacokinetics is unknown; however, metaxalone undergoes extensive hepatic metabolism <content styleCode="italics">[see <linkHtml href="#L51bf7da3-a625-4cfb-a56f-bf3df03963df">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="L93ff90ff-b6c0-43fd-88fb-8c9f840ea5d0">
                     <id root="63a96e22-a55f-4873-b9c2-2c8d417993bd"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Renal Impairment</title>
                     <text>
                        <paragraph>Metaxalone Tablets, 640 mg are contraindicated in patients with severe renal impairment<content styleCode="italics">. </content>Metaxalone Tablets, 640 mg should be used with caution and additional monitoring should be considered in patients with mild to moderate renal impairment. The effect of renal impairment on metaxalone pharmacokinetics is unknown; however, metaxalone undergoes renal excretion as unidentified metabolites <content styleCode="italics">[see <linkHtml href="#L51bf7da3-a625-4cfb-a56f-bf3df03963df">Clinical Pharmacology (12.3)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L1dc5d5d6-29ac-48c6-a9fa-96907f4c82dc">
               <id root="b9b4a2da-19ce-4a19-b8e3-29054f4e4127"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Clinical Presentations of Metaxalone Overdose</content>
                  </paragraph>
                  <paragraph>Cardiovascular effects may include tachycardia and hypertension; hypotension has also been reported. CNS manifestations may include CNS depression, agitation, hallucinations, delusions, seizures, respiratory depression, and coma. Deaths by deliberate or accidental overdose may occur with metaxalone, particularly in combination with other CNS depressants (including alcohol). Serotonin syndrome, leading to muscle rigidity, tremor, and hyperthermia, has been reported <content styleCode="italics">[see <linkHtml href="#Laa73a6ef-00cc-40a9-8a9e-4869ba0c3b2b">Warnings and Precautions (5.1)</linkHtml>, <linkHtml href="#L718e5aba-deb7-44d4-a34b-1ba1729b2725">Drug Interactions (7.1</linkHtml>, <linkHtml href="#Lb540b148-9955-41bc-80fc-ae7532630b1e">7.2)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Treatment of Overdose</content>
                  </paragraph>
                  <paragraph>The standard of treatment is supportive care. Monitor for CNS and respiratory depression and, manage airway with oxygen as needed. Gastrointestinal decontamination procedures (including emesis) should generally be avoided because aspiration may result from CNS depression and seizures. Extracorporeal elimination such as hemodialysis or plasmapheresis have no proven clinical benefit.</paragraph>
                  <paragraph>Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.</paragraph>
               </text>
               <effectiveTime value="20250512"/>
            </section>
         </component>
         <component>
            <section ID="L76717ba3-99b1-47d8-9870-35c4fb193bb4">
               <id root="5b4ccedb-6672-4354-8782-b3bf97e5d8f5"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Metaxalone Tablets, 640 mg for oral administration, are available as 640 mg oval, peach-colored tablets, debossed with M640 on one side and no markings on the other side. Each tablet contains 640 mg metaxalone, a muscle relaxant, and the following inactive ingredients: alginic acid, FD&amp;C yellow #6, lactose monohydrate, magnesium stearate, propylene glycol alginate and povidone.</paragraph>
                  <paragraph>Chemically, metaxalone is 5-[(3, 5- dimethylphenoxy) methyl]-2-oxazolidinone. The empirical formula is C<sub>1</sub>
                     <sub>2</sub>H<sub>15</sub>NO<sub>3</sub>, which corresponds to a molecular weight of 221.25. The structural formula is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lad5b2a22-39b8-459e-988d-e82c60b8b981"/>
                  </paragraph>
                  <paragraph styleCode="Default">Metaxalone is a white to almost white, odorless crystalline powder freely soluble in chloroform, soluble in methanol and in 96% ethanol, but practically insoluble in ether or water.</paragraph>
               </text>
               <effectiveTime value="20250512"/>
               <component>
                  <observationMedia ID="Lad5b2a22-39b8-459e-988d-e82c60b8b981">
                     <text>structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="structure001.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lff8c6d9c-1f85-4798-86b1-cce315401d73">
               <id root="6d4d4956-3267-4334-a55a-62b981427444"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12  CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250512"/>
               <component>
                  <section ID="Ld0b314e9-a02c-4b98-93b9-354194738c7c">
                     <id root="47928e5c-7808-4306-988f-289c689723da"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph styleCode="Default First">The mechanism of action of metaxalone as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions has not been established, but may be due to general CNS depression. Metaxalone has no direct action on the contractile mechanism of striated muscle, the motor end plate, or the nerve fiber.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="L23bf05f7-84f1-4ef7-bcde-6de8a9580216">
                     <id root="96c2e4b2-eac9-49d3-b1e8-ca472145497c"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of metaxalone not been fully characterized.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="L51bf7da3-a625-4cfb-a56f-bf3df03963df">
                     <id root="0ee6ba78-cdc8-4ba7-9008-657e97583240"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>In a relative bioavailability study in healthy adult volunteers, the C<sub>max </sub>(peak plasma concentration) and AUC (extent of absorption) values of metaxalone from Metaxalone Tablets, 640 mg were found to be similar to those from SKELAXIN 800 mg tablets. After a single dose of Metaxalone Tablets, 640 mg, under fasted conditions, mean C<sub>max </sub>and AUC values were 2 mcg/mL and 16 mcg*h/mL, respectively. The time-to-peak plasma concentration (T<sub>max</sub>) occurred at 3.5 hours (range 1.5-12 hours). The plasma half-life in adult healthy subjects was approximately 5 hours after administration of Metaxalone Tablets, 640 mg.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Food</content>: Table 1 displays the effect of a high fat meal on the pharmacokinetics of metaxalone.</paragraph>
                        <table width="100%">
                           <caption>Table 1: Effect of a High Fat Meal on the Pharmacokinetics of Metaxalone </caption>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">
                                    <content styleCode="bold"> Metaxalone Product</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">
                                    <content styleCode="bold"> C<sub>max</sub>
                                       <sup>1</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">
                                    <content styleCode="bold"> AUC<sub>0-t</sub>
                                       <sup>1</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">
                                    <content styleCode="bold"> AUC<sub>0-inf</sub>
                                       <sup>1</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">
                                    <content styleCode="bold"> T<sub>max</sub>
                                       <sup>2</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Lrule Rrule Toprule Botrule"> Metaxalone Tablets, 640 mg</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule Botrule"> 23% Increase</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule Botrule"> 7% Increase</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule Botrule"> 6% Increase</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule Botrule"> 8 hours<br/>(3.5-24 hours)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> SKELAXIN (metaxalone) tablets, 800 mg</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule Botrule"> 76% Increase</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule Botrule"> 32% Increase</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule Botrule"> 32% Increase</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule Botrule"> 5 hours<br/>(2.5-24 hours)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>1= Presented as ratio fed/fasted groups. Fed group received a high fat meal.<br/>2= Presented as median (range) under fed state.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>For Metaxalone Tablets, 640 mg, the metaxalone apparent volume of distribution (V/F) was approximately 800 Liters. Metaxalone plasma protein binding is unknown.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>For Metaxalone Tablets, 640 mg, the metaxalone plasma half-life was approximately 5 hours.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism:  </content>Metaxalone is metabolized by the liver. CYP1A2, CYP2D6, CYP2E1, and CYP3A4 and, to a lesser extent, CYP2C8, CYP2C9, and CYP2C19 are involved in metaxalone metabolism.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion: </content>Metaxalone is excreted in the urine as unidentified metabolites.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>For Metaxalone Tablets, 640 mg, the effect of age, renal impairment, and hepatic impairment on the pharmacokinetics of metaxalone is unknown.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Males and Females: </content>The metaxalone Cmax increased by 36% and AUC inf by 31%, in females compared to males following administration of 640 mg of Metaxalone Tablets. These data were not adjusted for other factors (e.g., weight, renal function).  The clinical significance of these findings is unknown.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In Vitro Studies: </content>Metaxalone does not inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 or induce CYP1A2, CYP2B6, and CYP3A4.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lc09c1e0b-3e38-44f5-b843-b48a6d8dbb2a">
               <id root="1613a513-f2b2-49f0-8f8e-23125f3ff494"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250512"/>
               <component>
                  <section ID="L03fd3f46-a65c-4d8d-b5dc-1ec333300df3">
                     <id root="e5871977-cfd0-432f-a88f-947550a98c38"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>Long-term studies to evaluate the carcinogenic potential of metaxalone have not been conducted.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Studies to evaluate the mutagenic potential of metaxalone have not been conducted.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Reproduction studies in rats have not revealed evidence of impaired fertility or harm to the fetus due to metaxalone.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_55894901-6f71-4449-9b18-6bfaedd526cd">
               <id root="7efe0bac-acc2-41d9-a7d0-04bc3ed10db9"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Metaxalone Tablets, 640 mg are available as oval, peach-colored tablets, debossed with M640 on one side and no markings on the other side. Metaxalone Tablets, 640 mg are packaged as a bottle of 60 tablets, NDC 74157-018-60</paragraph>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). [see USP Controlled Room Temperature].</paragraph>
               </text>
               <effectiveTime value="20250512"/>
            </section>
         </component>
         <component>
            <section ID="Le8728282-823e-4919-aa05-56954e3a1fb4">
               <id root="77d99690-c0b9-4617-bf94-01aa53f5736b"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Serotonin Syndrome</content>
                  </paragraph>
                  <paragraph>Inform patients that Metaxalone Tablets, 640 mg could cause a rare but potentially life-threatening condition called serotonin syndrome. Warn patients of the symptoms of serotonin syndrome and to seek medical attention right away if symptoms develop. Instruct patients to inform their healthcare providers if they are taking, or plan to take, serotonergic drugs <content styleCode="italics">[see <linkHtml href="#Laa73a6ef-00cc-40a9-8a9e-4869ba0c3b2b">Warnings and Precautions (5.1)</linkHtml> and <linkHtml href="#L718e5aba-deb7-44d4-a34b-1ba1729b2725">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Central Nervous System Depression</content>
                  </paragraph>
                  <paragraph>Advise patients that Metaxalone Tablets, 640 mg may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle, especially when used with alcohol and other CNS depressants <content styleCode="italics">[see <linkHtml href="#Lb540b148-9955-41bc-80fc-ae7532630b1e">Drug Interactions (7.2)</linkHtml>]</content>.</paragraph>
                  <paragraph>Manufactured for: INA Pharmaceutics, Inc., Fairmont, WV 26554 <br/> 21507-02 05/25 <br/> 1274C##</paragraph>
               </text>
               <effectiveTime value="20250512"/>
            </section>
         </component>
         <component>
            <section ID="Lfaff08d6-7845-4e4f-9603-4e2d9b845faa">
               <id root="5cc4a464-68e8-489c-9e56-61c4ad5c401b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Product label</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 74157-018-60</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Metaxalone Tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">640 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">SEALED FOR YOYR PROTECTION</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">60 Tablets</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Led553a65-ea6f-40d2-aa3f-f9a299716eb2"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250512"/>
               <component>
                  <observationMedia ID="Led553a65-ea6f-40d2-aa3f-f9a299716eb2">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>